Adaptive Biotechnologies Corporation logo
Adaptive Biotechnologies Corporation ADPT
$ 24.28 1.31%
report update icon

Quarterly report 2026-Q2
added 08-04-2026

Adaptive Biotechnologies Corporation Cash Flow 2025-2011 | ADPT

Brief cash flow overview of Adaptive Biotechnologies Corporation

The review uses the five latest available annual reports between 2021 and 2025.

Cash from operations is below zero at -$46 million, increasing dependence on cash reserves or outside financing.

Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.

Working capital grew $20.4 million, or 7.3% of sales. Part of cash generation funded day-to-day operations.

Overall picture

Adaptive Biotechnologies Corporation has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.

Annual Cash Flow Adaptive Biotechnologies Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-46 M -95.2 M -156 M -184 M -193 M -150 M 205 M -32.3 M -34.9 M - - - - - -

Depreciation & Amortization

16 M 17.4 M 19.6 M 20.9 M 12.3 M 6.77 M 6.09 M 4.3 M 4.1 M - - - - - -

Accounts Payables

6.47 M 7.26 M 7.72 M 8.08 M 3.31 M 3.24 M 4.45 M - - - - - - - -

Accounts Receivables

50.4 M 41.7 M 38 M 40.1 M 17.4 M 10 M 12.7 M - - - - - - - -

Total Inventories

9.82 M 8.44 M 14.4 M 14.5 M 19.3 M 14.1 M 9.07 M - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Adaptive Biotechnologies Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-15.9 M -9.54 M - - - -28.5 M - - - -38.4 M - - - -59.2 M - -154 M - -64.5 M - -139 M - -58.2 M - -110 M -62.7 M -31.6 M - 232 M 262 M 278 M - -26.8 M -15.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

6.69 M 3.39 M - 3.97 M 4.07 M 4.29 M - 4.16 M 4.57 M 5.21 M - 5.76 M 5.65 M 5.42 M - 428 K 423 K 4.64 M - 7.83 M 423 K 2.25 M - 4.84 M 3.13 M 1.55 M - 4.45 M 2.81 M 1.36 M - 3.14 M 2.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

5.24 M 9.62 M 6.47 M 10.3 M 6.91 M 6.36 M 7.26 M 7.35 M 9.87 M 12.2 M 7.72 M 4.48 M 9.16 M 6.33 M 8.08 M 4.16 M - 5.96 M 3.31 M 8.25 M 6.09 M 5.2 M 3.24 M 3.24 M 3.24 M 3.24 M 4.45 M 4.45 M 4.45 M 4.45 M 1.79 M 1.79 M 1.79 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

49.5 M 48.3 M 50.4 M 44.8 M 44.3 M 43.6 M 41.7 M 40.8 M 35.6 M 42 M 38 M 31.2 M 31.5 M 31 M 40.1 M 26.5 M - 22.5 M 17.4 M 17.1 M 14.2 M 19.8 M 10 M 10 M 10 M 10 M 12.7 M 12.7 M 12.7 M 12.7 M 4.81 M 4.81 M 4.81 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

10.5 M 11.2 M 9.82 M 9.93 M 8.4 M 8.68 M 8.44 M 12 M 13.2 M 13.3 M 14.4 M 19.5 M 19 M 19.9 M 14.5 M 17.3 M - 21 M 19.3 M 18.2 M 18.6 M 17.4 M 14.1 M 14.1 M 14.1 M 14.1 M 9.07 M 9.07 M 9.07 M 9.07 M 7.84 M 7.84 M 7.84 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Adaptive Biotechnologies Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA